Clinical Quantitative Mass Spectrometry Proteomics (WG-cMSP)

 

Membership 

Name Position Country Term Time in Office
S.  Lehmann Chair FR 1st 2011 01 - 2013 12
E.O.  Agbedana Member NG    
Y.  Ando Member JP    
C.  Brede Member NO    
U.  Ceglarek Member DE    
J.A.  Cocho Member ES    
M.  Glückmann Member DE    
Y.  Gong Member CA    
D.  Hochstrasser Member CH    
A.  Hoofnagle Member US    
BE.  Krastin Member US    
C.  Queijo Member UY    
A.  Urbani Member IT

 

Terms of Reference

  • To review the state of the art in quantitative proteomics and to evaluate the capacity of different analytical (and preanalytical) approaches to play in the future a significant role for clinical biology
  • To evaluate the specification and the need for reference materials for quantitative proteomics applied to clinical biology
  • To design of a Quality Assurance/Quality Control (QA/QC) Program and to select a small series of analytes to be the subject of a future multi-site validation study

 

Current Projects

  • Collect information related to the above "Terms of Reference" to propose a "road map/white paper" on "Clinical Chemistry Proteomics", i.e. the application of Clinical Proteomics to Clinical Chemistry
  • Decision on the optimum analyte for the assessment of Clinical Quantitative Mass Spectrometry Proteomics in a multi-site validation study.
  • Organize a symposia/session in a future international meeting
  • Coordination with HUPO/EuPA latest initiatives on the Human Proteome Project and in particular on the mass spectrometry based quantitative assays.

Working Group Chairs'  contact

Prof. Sylvain LEHMANN
CHU de Montpellier - Hôpital St. Eloi
Institut de Recherches en Biothérapie (IRB)
Biochimie - Protéomique Clinique
80, av A. Fliche
34295 Montpellier Cedex 5
FRANCE
Tel: +33 04 67 33 71 23 / +33 04 67 33 71 24
Fax: +33 04 67 33 69 21
E-mail: s-lehmann@chu-montpellier.fr



 

 

 

Site udviklet af Insoft Digital